Lode Denolf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lode Denolf has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Kris Gevaert
Ghent University
3 shared publications - Béatrice Lintermans
Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
2 shared publications - Charlotte Fieuws
Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
2 shared publications - Geert Berx
Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
2 shared publications Joachim Taminau
Cancer Research Institute Ghent (CRIG) Belgium
2 shared publications- Kathleen Bertha Michaël Claes
Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
2 shared publications
Latest Publications
- Open Access
- 18 June 2025
- Published by Wiley in Molecular Oncology
- Vol. 19 (11) , 3360-3375
EMT ‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines
Pancreatic cancer has a 5‐year survival rate of 12%, highlighting the need for reliable biomarkers for early detection and disease monitoring. Circulating tumor cells (CTCs) have emerged as a promising biomarker, yet their detection remains challenging. This study evaluates the Parsortix® system, a microfluidic device that enriches CTCs based on size and deformability, using pancreatic cancer cell lines. As increasing evidence indicates that during epithelial‐to‐mesenchymal transition (EMT) a cell's deformability increases, we evaluated possible biases by the device. The EMT stage of three pancreatic cancer cell lines, CAPAN‐1, MIA PaCa‐2, and PANC‐1, was assessed to classify them as epithelial, mesenchymal‐like, and hybrid, respectively. Spike‐in experiments showed that epithelial and hybrid phenotypes were more efficiently captured (62.6 ± 18.5% and 65.4 ± 11.1%) than mesenchymal‐like cancer cells (32.8 ± 10.2%). These results were confirmed using an EMT‐inducible breast cancer cell line. Lower recovery rates were found for the cells in a mesenchymal‐like state (31.5 ± 6.4%) than those in an epithelial state (47.56 ± 7.2%). In conclusion, the Parsortix® device may underestimate the number of mesenchymal CTCs.
- 18 June 2025
- Published by Wiley in Molecular Oncology
- Vol. 19 (11) , 3360-3375
Open AccessEMT ‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines
Pancreatic cancer has a 5‐year survival rate of 12%, highlighting the need for reliable biomarkers for early detection and disease monitoring. Circulating tumor cells (CTCs) have emerged as a promising biomarker, yet their detection remains challenging. This study evaluates the Parsortix® system, a microfluidic device that enriches CTCs based on size and deformability, using pancreatic cancer cell lines. As increasing evidence indicates that during epithelial‐to‐mesenchymal transition (EMT) a cell's deformability increases, we evaluated possible biases by the device. The EMT stage of three pancreatic cancer cell lines, CAPAN‐1, MIA PaCa‐2, and PANC‐1, was assessed to classify them as epithelial, mesenchymal‐like, and hybrid, respectively. Spike‐in experiments showed that epithelial and hybrid phenotypes were more efficiently captured (62.6 ± 18.5% and 65.4 ± 11.1%) than mesenchymal‐like cancer cells (32.8 ± 10.2%). These results were confirmed using an EMT‐inducible breast cancer cell line. Lower recovery rates were found for the cells in a mesenchymal‐like state (31.5 ± 6.4%) than those in an epithelial state (47.56 ± 7.2%). In conclusion, the Parsortix® device may underestimate the number of mesenchymal CTCs.
- Open Access
- 20 March 2025
- Published by Springer Nature in EMBO Reports
- Vol. 26 (9) , 2378-2412
Lack of AtMC1 catalytic activity triggers autoimmunity dependent on NLR stability
Plants utilize cell surface-localized pattern recognition receptors (PRRs) and intracellular nucleotide-binding leucine-rich repeat (NLR) receptors to detect non-self and elicit robust immune responses. Fine-tuning the homeostasis of these receptors is critical to prevent their hyperactivation. Here, we show that Arabidopsis plants lacking metacaspase 1 ( At MC1) display autoimmunity dependent on immune signalling components downstream of NLR and PRR activation. Overexpression of a catalytically inactive At MC1 in an atmc1 background triggers severe autoimmunity partially dependent on the same immune signalling components. Overexpression of the E3 ligase SNIPER1, a master regulator of NLR homeostasis, fully reverts the AtMC1-dependent autoimmunity phenotype, inferring that a broad defect in NLR turnover may underlie the severe phenotype observed. Catalytically inactive At MC1 localizes to punctate structures that are degraded through autophagy. Considering also previous evidence on the proteostatic functions of At MC1, we speculate that Wt At MC1 may either directly or indirectly control NLR protein levels, thereby preventing autoimmunity.
- 20 March 2025
- Published by Springer Nature in EMBO Reports
- Vol. 26 (9) , 2378-2412
Open AccessLack of AtMC1 catalytic activity triggers autoimmunity dependent on NLR stability
Plants utilize cell surface-localized pattern recognition receptors (PRRs) and intracellular nucleotide-binding leucine-rich repeat (NLR) receptors to detect non-self and elicit robust immune responses. Fine-tuning the homeostasis of these receptors is critical to prevent their hyperactivation. Here, we show that Arabidopsis plants lacking metacaspase 1 ( At MC1) display autoimmunity dependent on immune signalling components downstream of NLR and PRR activation. Overexpression of a catalytically inactive At MC1 in an atmc1 background triggers severe autoimmunity partially dependent on the same immune signalling components. Overexpression of the E3 ligase SNIPER1, a master regulator of NLR homeostasis, fully reverts the AtMC1-dependent autoimmunity phenotype, inferring that a broad defect in NLR turnover may underlie the severe phenotype observed. Catalytically inactive At MC1 localizes to punctate structures that are degraded through autophagy. Considering also previous evidence on the proteostatic functions of At MC1, we speculate that Wt At MC1 may either directly or indirectly control NLR protein levels, thereby preventing autoimmunity.
- Open Access
Biases in the Parsortix® system observed with pancreatic cancer cell lines
Pancreatic cancer has a 5-year survival rate of merely 12%. The high rate of late-stage diagnoses underscores the need for reliable biomarkers for early detection and disease monitoring. Circulating tumor cells (CTCs) have emerged as a promising biomarker, yet their detection remains challenging due to their rarity and phenotypic diversity. This study evaluates the Parsortix® system, a microfluidic device designed to enrich CTCs based on size and deformability, using pancreatic cancer cell lines. As increasing evidence indicates that during epithelial to mesenchymal transition (EMT) a cell’s deformability increases, we evaluated to what extent the Parsortix® system was biased towards epithelial cancer cells. First, the EMT stage of three pancreatic cancer cell lines, CAPAN-1, PANC-1 and MIA PaCa-2, was assessed using immunocytochemistry, flow cytometry and proteomics. CAPAN-1 cells were classified as epithelial, MIA PaCa-2 cells exhibited a mesenchymal-like phenotype, and PANC-1 cells demonstrated a hybrid phenotype. Then, by spiking these cells into blood samples, we determined the Parsortix® system’s ability to recover the cancer cells. Our results indicated that epithelial and hybrid phenotypes are more efficiently captured (62.6 ± 18.5% and 65.4 ± 11.1%) than mesenchymal cancer cells (32.8 ± 10.2%). To confirm these findings, spike-in experiments were repeated using an EMT inducible cell line. Again, significantly lower recovery rates were found for the cells in a mesenchymal-like state (31.5 ± 6.4%) compared to those in an epithelial state (47.56 ± 7.2%). In conclusion, the Parsortix® system may underestimate the presence of mesenchymal CTCs.
Open AccessBiases in the Parsortix® system observed with pancreatic cancer cell lines
Pancreatic cancer has a 5-year survival rate of merely 12%. The high rate of late-stage diagnoses underscores the need for reliable biomarkers for early detection and disease monitoring. Circulating tumor cells (CTCs) have emerged as a promising biomarker, yet their detection remains challenging due to their rarity and phenotypic diversity. This study evaluates the Parsortix® system, a microfluidic device designed to enrich CTCs based on size and deformability, using pancreatic cancer cell lines. As increasing evidence indicates that during epithelial to mesenchymal transition (EMT) a cell’s deformability increases, we evaluated to what extent the Parsortix® system was biased towards epithelial cancer cells. First, the EMT stage of three pancreatic cancer cell lines, CAPAN-1, PANC-1 and MIA PaCa-2, was assessed using immunocytochemistry, flow cytometry and proteomics. CAPAN-1 cells were classified as epithelial, MIA PaCa-2 cells exhibited a mesenchymal-like phenotype, and PANC-1 cells demonstrated a hybrid phenotype. Then, by spiking these cells into blood samples, we determined the Parsortix® system’s ability to recover the cancer cells. Our results indicated that epithelial and hybrid phenotypes are more efficiently captured (62.6 ± 18.5% and 65.4 ± 11.1%) than mesenchymal cancer cells (32.8 ± 10.2%). To confirm these findings, spike-in experiments were repeated using an EMT inducible cell line. Again, significantly lower recovery rates were found for the cells in a mesenchymal-like state (31.5 ± 6.4%) compared to those in an epithelial state (47.56 ± 7.2%). In conclusion, the Parsortix® system may underestimate the presence of mesenchymal CTCs.